Telomir Pharmaceuticals, Inc. Operating Cash Flow
Telomir Pharmaceuticals, Inc. (TELO) reported Operating Cash Flow of -$2.79 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-13.
Financial Statements › Cash Flow › Operating Activities
us-gaap:NetCashProvidedByUsedInOperatingActivities · last filed 2026-08-13
- Telomir Pharmaceuticals, Inc. net cash provided by (used in) operating activities for the quarter ending 2026-06-30 was -$1.01M.
- Telomir Pharmaceuticals, Inc. net cash provided by (used in) operating activities for the quarter ending 2026-03-31 was -$1.77M.
- Telomir Pharmaceuticals, Inc. net cash provided by (used in) operating activities for the quarter ending 2025-12-31 was -$1.20M.
- Telomir Pharmaceuticals, Inc. net cash provided by (used in) operating activities for the quarter ending 2025-09-30 was -$927.26K.
- Telomir Pharmaceuticals, Inc. net cash provided by (used in) operating activities for fiscal 2025 was -$3.69M.
- Telomir Pharmaceuticals, Inc. net cash provided by (used in) operating activities for fiscal 2024 was -$5.07M.
- Telomir Pharmaceuticals, Inc. net cash provided by (used in) operating activities for fiscal 2023 was -$3.86M.
- Telomir Pharmaceuticals, Inc. net cash provided by (used in) operating activities for fiscal 2022 was -$468.66K.
| Period end | Net Cash Provided by (Used in) Operating Activities 3 month | Net Cash Provided by (Used in) Operating Activities 6 month | Net Cash Provided by (Used in) Operating Activities 9 month | Net Cash Provided by (Used in) Operating Activities 12 month |
|---|---|---|---|---|
| 2026-06-30 | -$1.01M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-13 | -$2.79M 10-Q · filed 2026-08-13 | -$3.99M derived: sum of 3 quarters · filed 2026-08-13 | -$4.91M derived: sum of 4 quarters · filed 2026-08-13 |
| 2026-03-31 | -$1.77M 10-Q · filed 2026-05-14 | -$2.97M derived: sum of 2 quarters · filed 2026-05-14 | -$3.90M derived: sum of 3 quarters · filed 2026-05-14 | -$4.60M derived: sum of 4 quarters · filed 2026-08-13 |
| 2025-12-31 | -$1.20M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-17 | -$2.13M derived: sum of 2 quarters · filed 2026-03-17 | -$2.83M derived: sum of 3 quarters · filed 2026-08-13 | -$3.69M 10-K · filed 2026-03-17 |
| 2025-09-30 | -$927.26K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-10 | -$1.62M derived: sum of 2 quarters · filed 2026-08-13 | -$2.49M 10-Q · filed 2025-11-10 | -$3.09M derived: sum of 4 quarters · filed 2026-08-13 |
| 2025-06-30 | -$696.45K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-13 | -$1.56M 10-Q · filed 2026-08-13 | -$2.17M derived: sum of 3 quarters · filed 2026-08-13 | -$3.17M derived: sum of 4 quarters · filed 2026-08-13 |
| 2025-03-31 | -$863.13K 10-Q · filed 2026-05-14 | -$1.47M derived: sum of 2 quarters · filed 2026-05-14 | -$2.47M derived: sum of 3 quarters · filed 2026-05-14 | -$3.99M derived: sum of 4 quarters · filed 2026-05-14 |
| 2024-12-31 | -$605.81K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-17 | -$1.61M derived: sum of 2 quarters · filed 2026-03-17 | -$3.13M derived: sum of 3 quarters · filed 2026-03-17 | -$5.07M 10-K · filed 2026-03-17 |
| 2024-09-30 | -$1.00M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-10 | -$2.53M derived: sum of 2 quarters · filed 2025-11-10 | -$4.46M 10-Q · filed 2025-11-10 | -$5.55M derived: sum of 4 quarters · filed 2025-11-10 |
| 2024-06-30 | -$1.52M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-14 | -$3.46M 10-Q · filed 2025-08-14 | -$4.55M derived: sum of 3 quarters · filed 2025-08-14 | -$6.55M derived: sum of 4 quarters · filed 2025-08-14 |
| 2024-03-31 | -$1.94M 10-Q · filed 2025-05-14 | -$3.03M derived: sum of 2 quarters · filed 2025-05-14 | -$5.03M derived: sum of 3 quarters · filed 2025-05-14 | -$5.06M derived: sum of 4 quarters · filed 2025-05-14 |
| 2023-12-31 | -$1.09M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-04 | -$3.09M derived: sum of 2 quarters · filed 2025-02-04 | -$3.12M derived: sum of 3 quarters · filed 2025-02-04 | -$3.86M 10-K · filed 2025-02-04 |
| 2023-09-30 | -$2.00M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-12 | -$2.04M derived: sum of 2 quarters · filed 2024-11-12 | -$2.77M 10-Q · filed 2024-11-12 | |
| 2023-06-30 | -$33.58K derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-13 | -$769.32K 10-Q · filed 2024-08-13 | ||
| 2023-03-31 | -$735.74K 10-Q · filed 2024-05-13 | |||
| 2022-12-31 | -$468.66K 10-K · filed 2024-03-29 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Lexaria Bioscience Corp. (LEXX) | $0.084B | -1.92 | |
| NEONC TECHNOLOGIES HOLDINGS, INC. (NTHI) | United States | $0.086B | |
| ONCOLYTICS BIOTECH INC (ONCY) | $0.086B | ||
| Gain Therapeutics, Inc. (GANX) | United States | $0.080B | -4.40 |
| Rallybio Corp (RLYB) | United States | $0.089B | |
| Lifevantage Corp (LFVN) | United States | $0.078B | 15.40 |
| Adicet Bio, Inc. (ACET) | United States | $0.078B | -0.81 |
| Valion Bio, Inc. (VBIO) | United States | $0.077B | |
| MAIA Biotechnology, Inc. (MAIA) | United States | $0.077B | -2.30 |
| iBio, Inc. (IBIO) | United States | $0.077B | -2.94 |